Novartis International AG http://www.novartis.com <![CDATA[Novartis highlights innovative approach to drug discovery with dynamic advance in exploratory pipeline]]> 2008-11-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1271207.shtml <![CDATA[Rasilez®, first-in-class direct renin inhibitor, provides greater reduction in high blood pressure than ACE inhibitor ramipril in patients 65 and older]]> 2008-11-11T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1268561.shtml <![CDATA[Rasilez HCT®, single-pill combination of Rasilez® and diuretic, receives Swiss approval for the treatment of high blood pressure]]> 2008-10-29T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1264205.shtml <![CDATA[ACZ885 Phase III data show rapid, sustained clinical remission in children and adults suffering from a group of rare, potentially life-threatening autoinflammatory diseases]]> 2008-10-27T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1263270.shtml <![CDATA[Novartis to acquire Nektar Therapeutics pulmonary business unit, strengthening respiratory drug delivery capabilities]]> 2008-10-21T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1261361.shtml <![CDATA[Novartis delivers sustained strong performance in first nine months of 2008 underpinned by accelerating growth in pharmaceuticals]]> 2008-10-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1260877.shtml <![CDATA[Early data show potential for imatinib to treat life-threatening form of pulmonary artery disease]]> 2008-10-08T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1257684.shtml <![CDATA[New Phase II data on NVA237, a novel once-daily treatment for COPD, show promising efficacy and tolerability with potentially faster onset than tiotropium]]> 2008-10-07T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1257283.shtml <![CDATA[New study shows potential benefits of innovative Xolair® anti-IgE therapy in treating children suffering from moderate-to-severe allergic asthma ]]> 2008-10-06T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1257049.shtml <![CDATA[Once-yearly Aclasta® approved in EU to treat osteoporosis in men and to reduce risk of new fractures following hip fracture both in men and postmenopausal women]]> 2008-09-30T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1255392.shtml